Related Experiment Video

Updated: Aug 14, 2026

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
09:12

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Hypoxia-targeted bioreductive tyrosine kinase inhibitors with glutathione-depleting function

Rangaprasad Sarangarajan1, Shireesh P Apte, Sydney O Ugwu

  • 1Department of Pharmaceutical Sciences, Massachusetts College of Pharmacy and Health Sciences, Worcester, Massachusetts, USA.

Anti-Cancer Drugs
|December 1, 2005
PubMed

Insights

Tyrosine kinase inhibitors can be modified to target tumors, reducing toxicity. This novel approach leverages hypoxia-activated molecules to inhibit tumor kinases, disrupt DNA, and induce apoptosis via glutathione depletion.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Tyrosine kinase inhibitors (TKIs) can cause toxicity by affecting normal cell kinases.
  • Targeting TKIs specifically to tumor cells is a significant challenge in cancer therapy.

Purpose of the Study:

  • To develop a novel strategy for targeted delivery of TKIs to tumor cells.
  • To explore a multi-mechanism approach for enhanced cancer cell killing.

Main Methods:

  • Coupling TKIs to hypoxia-activated bioreductive molecules.
  • Utilizing bonds susceptible to oxidation by intracellular glutathione (GSH).
  • Investigating the effects of GSH depletion on redox-mediated apoptosis.

Main Results:

  • The designed molecules are projected to inhibit tumor kinases.
  • The approach aims to disrupt tumor DNA.
  • Increased redox-mediated apoptosis is anticipated due to GSH depletion.

Conclusions:

  • This strategy offers a potential method for targeted TKI delivery, minimizing systemic toxicity.
  • The resultant molecules are designed to induce cancer cell death through multiple mechanisms.
  • Further research may validate this approach for improved cancer treatment outcomes.

More Related Videos

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...